Evaluating promising new treatments for life-threatening disease: implications of the HDC/ABMT experience for treating breast cancer.
Edwards
Susan
S
AcademyHealth, Washington, DC, USA. susan.edwards@academyhealth.org
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D016026:Bone Marrow Transplantation; D001943:Breast Neoplasms / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004059:Diffusion of Innovation; D005260:Female; D006301:Health Services Needs and Demand; D006801:Humans; D009316:National Institutes of Health (U.S.); D016032:Randomized Controlled Trials as Topic; D012945:Social Values; D013673:Technology Assessment, Biomedical; D013675:Technology, High-Cost; D014182:Transplantation, Autologous; D014481:United States
D000970:Antineoplastic Agents